Loading...
•
Dec 31, 2021
Kiniksa Q4 2021 Earnings Report
Kiniksa reported fourth quarter and full-year 2021 financial results and provided a corporate update.
Key Takeaways
Kiniksa announced ARCALYST collaboration achieved profitability in Q4 2021. They anticipate continued robust commercial execution and the further advancement of their clinical-stage pipeline in 2022. A strategic collaboration with Huadong Medicine was established to develop and commercialize ARCALYST and mavrilimumab in the Asia Pacific Region (excluding Japan).
ARCALYST collaboration achieved profitability in Q4 2021.
ARCALYST full-year 2022 net revenue expected to be $115 - $130 million.
Strategic collaboration with Huadong Medicine to develop and commercialize ARCALYST and mavrilimumab in the Asia Pacific Region (excluding Japan).
Phase 2b study of vixarelimab in prurigo nodularis data expected in the second half of 2022.
Forward Guidance
Kiniksa expects continued robust commercial execution and further advancement of its clinical-stage pipeline in 2022.
Positive Outlook
- Continued robust commercial execution.
- Further advancement of clinical-stage pipeline.
- Data from the Phase 2b study of vixarelimab in prurigo nodularis expected in the second half of 2022.
- Continued enrollment in the Phase 2 trial of KPL-404 in rheumatoid arthritis in 2022.
- Collaboration with Huadong Medicine provides non-dilutive capital and the opportunity to accelerate the development of ARCALYST and mavrilimumab.
Challenges Ahead
- Delays or difficulty in enrollment of patients in clinical trials.
- Potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials.
- Inability to replicate results from earlier clinical trials or studies.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...